Effects of formulation and operating variables on zanamivir dry powder inhalation characteristics and aerosolization performance
- PMID: 24491208
- DOI: 10.3109/10717544.2014.883113
Effects of formulation and operating variables on zanamivir dry powder inhalation characteristics and aerosolization performance
Abstract
Abstract The objective of this study was to investigate the influence of formulation and operating variables on the physical characteristics and aerosolization performance of zanamivir spary-dried powders for inhalation. Spray-dried samples of zanamivir, zanamivir/mannitol and zanamivir/mannitol/leucine were prepared from their corresponding aqueous solutions under the same conditions to study the influence of the composition, and zanamivir/mannitol/leucine (1/1/3 by weight) formulation was used for investigation of the effect of the preparation process. Dry powders were characterized afterwards for different physical properties, including morphology, particle size, flowability, density and moisture absorption. The in vitro deposition was also evaluated after the aerosolization of powders at 100 L min(-1) via the Aerolizer® into a Next Generation Impactor (NGI). The highest FPF of 41.40 ± 1.1% was obtained with a zanamivir/mannitol/leucine ratio of 1/1/3, which had an average Dg of 3.11 ± 0.13 μm and an angle of repose of 36°( )± 1. It was found that the influence of the preparation process on zanamivir spary-dried powders characteristics and aerosolization properties was relatively small, but the influence of the composition was relatively large. Optimization of DPI can be achieved by selecting the most appropriate formulation and preparation process.
Keywords: Dry powder inhalations; Zanamivir; excipient; in vitro powder deposition; spray-drying.
Similar articles
-
L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.Eur J Pharm Biopharm. 2016 May;102:132-41. doi: 10.1016/j.ejpb.2016.02.010. Epub 2016 Mar 9. Eur J Pharm Biopharm. 2016. PMID: 26970252
-
Influence of formulation and preparation process on ambroxol hydrochloride dry powder inhalation characteristics and aerosolization properties.Drug Dev Ind Pharm. 2008 Sep;34(9):984-91. doi: 10.1080/03639040802154913. Drug Dev Ind Pharm. 2008. PMID: 18800258
-
Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation.Int J Pharm. 2018 Jun 10;544(1):222-234. doi: 10.1016/j.ijpharm.2018.04.034. Epub 2018 Apr 18. Int J Pharm. 2018. PMID: 29678544 Free PMC article.
-
Leucine as an excipient in spray dried powder for inhalation.Drug Discov Today. 2021 Oct;26(10):2384-2396. doi: 10.1016/j.drudis.2021.04.009. Epub 2021 Apr 17. Drug Discov Today. 2021. PMID: 33872799 Review.
-
Overcoming challenges for development of amorphous powders for inhalation.Expert Opin Drug Deliv. 2020 Nov;17(11):1583-1595. doi: 10.1080/17425247.2020.1813105. Epub 2020 Aug 31. Expert Opin Drug Deliv. 2020. PMID: 32811193 Review.
Cited by
-
Design of Experiment (DoE) Approach for Developing Inhalable PLGA Microparticles Loaded with Clofazimine for Tuberculosis Treatment.Pharmaceuticals (Basel). 2024 Jun 7;17(6):754. doi: 10.3390/ph17060754. Pharmaceuticals (Basel). 2024. PMID: 38931422 Free PMC article.
-
Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder.Pharmaceutics. 2022 Jul 8;14(7):1432. doi: 10.3390/pharmaceutics14071432. Pharmaceutics. 2022. PMID: 35890327 Free PMC article.
-
Glycoside scutellarin enhanced CD-MOF anchoring for laryngeal delivery.Acta Pharm Sin B. 2020 Sep;10(9):1709-1718. doi: 10.1016/j.apsb.2020.04.015. Epub 2020 May 7. Acta Pharm Sin B. 2020. PMID: 33088690 Free PMC article.
-
Lung Delivery of Lactose-Free Microparticles Loaded with Azithromycin for the Treatment of Bacterial Infections.Pharmaceutics. 2025 Jun 11;17(6):770. doi: 10.3390/pharmaceutics17060770. Pharmaceutics. 2025. PMID: 40574082 Free PMC article.
-
Spray-Dried Inhalable Microparticles Combining Remdesivir and Ebselen against SARS-CoV-2 Infection.Pharmaceutics. 2023 Aug 29;15(9):2229. doi: 10.3390/pharmaceutics15092229. Pharmaceutics. 2023. PMID: 37765198 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous